JP2021511372A5 - - Google Patents

Info

Publication number
JP2021511372A5
JP2021511372A5 JP2020560115A JP2020560115A JP2021511372A5 JP 2021511372 A5 JP2021511372 A5 JP 2021511372A5 JP 2020560115 A JP2020560115 A JP 2020560115A JP 2020560115 A JP2020560115 A JP 2020560115A JP 2021511372 A5 JP2021511372 A5 JP 2021511372A5
Authority
JP
Japan
Prior art keywords
approximately
seq
amino acid
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020560115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/013638 external-priority patent/WO2019143607A1/en
Publication of JP2021511372A publication Critical patent/JP2021511372A/ja
Publication of JP2021511372A5 publication Critical patent/JP2021511372A5/ja
Pending legal-status Critical Current

Links

JP2020560115A 2018-01-16 2019-01-15 Tim3に対する抗体で癌を処置する方法 Pending JP2021511372A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862617828P 2018-01-16 2018-01-16
US62/617,828 2018-01-16
US201862618561P 2018-01-17 2018-01-17
US62/618,561 2018-01-17
US201862633477P 2018-02-21 2018-02-21
US62/633,477 2018-02-21
PCT/US2019/013638 WO2019143607A1 (en) 2018-01-16 2019-01-15 Methods of treating cancer with antibodies against tim3

Publications (2)

Publication Number Publication Date
JP2021511372A JP2021511372A (ja) 2021-05-06
JP2021511372A5 true JP2021511372A5 (cg-RX-API-DMAC7.html) 2022-02-24

Family

ID=65516723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020560115A Pending JP2021511372A (ja) 2018-01-16 2019-01-15 Tim3に対する抗体で癌を処置する方法

Country Status (6)

Country Link
US (3) US20210363242A1 (cg-RX-API-DMAC7.html)
EP (1) EP3740506A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021511372A (cg-RX-API-DMAC7.html)
KR (1) KR20200109339A (cg-RX-API-DMAC7.html)
CN (1) CN111868091A (cg-RX-API-DMAC7.html)
WO (1) WO2019143607A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル-マイヤーズ スクイブ カンパニー Tim3に対する抗体およびその使用
CN113248612A (zh) * 2020-02-13 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗神经内分泌瘤中的用途
CN113214396B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
EP4083065A1 (en) 2021-01-28 2022-11-02 NantBio, Inc. Anti-tim3 monoclonal antibodies and chimeric antigen receptors
CN117377692A (zh) 2021-04-23 2024-01-09 苏州逻晟生物医药有限公司 Tim-3-靶向抗体及其用途
US20250230242A1 (en) * 2022-03-14 2025-07-17 Nanjing Shunxin Pharmaceuticals Co., Ltd. Of Chiatai Tianqing Pharm. Group Pharmaceutical composition of anti-tim-3 antibody and hypomethylating agent
US20250034255A1 (en) * 2023-03-08 2025-01-30 Incyte Corporation Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド TIM−3、Th1特異的細胞表面分子に関連した組成物および方法
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
AU2015340056A1 (en) 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
MY193661A (en) 2014-11-06 2022-10-24 Hoffmann La Roche Anti-tim3 antibodies and methods of use
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
AU2016229189A1 (en) 2015-03-06 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind TIM3
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
MA43028B1 (fr) 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
JP7082051B2 (ja) 2016-01-11 2022-06-07 アルモ・バイオサイエンシーズ・インコーポレイテッド 抗原特異的cd8+t細胞の産生におけるインターロイキン-10及びその使用方法
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
US20190248893A1 (en) * 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
AU2018205401B2 (en) * 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
CN111050791A (zh) * 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途

Similar Documents

Publication Publication Date Title
ES2749098T3 (es) Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico
ES2981830T3 (es) Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres
JP2018518454A5 (cg-RX-API-DMAC7.html)
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
US20180036395A1 (en) Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2017533912A5 (cg-RX-API-DMAC7.html)
CN121943909A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
Pan et al. Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
JP2024515879A5 (cg-RX-API-DMAC7.html)
Hwang et al. Emerging EGFR-targeted therapy in head and neck cancer: A review
CN111867598A (zh) 肿瘤免疫赋活剂
JP2023531090A5 (cg-RX-API-DMAC7.html)
TW202545570A (zh) 抗體藥物偶聯物和免疫檢查點抑制劑的聯合應用
WO2025082449A1 (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
JPWO2022270523A5 (cg-RX-API-DMAC7.html)
TWI671072B (zh) 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合
JP2024527180A5 (cg-RX-API-DMAC7.html)
TWI814752B (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
RU2778887C2 (ru) Комбинация трифлуридина/типирацил гидрохлорида, противоопухолевого платинового комплекса и модулятора контрольных точек иммунного ответа
HK40124723A (en) Combined use of an antibody-drug conjugate and an immune checkpoint inhibitor
HK40015395A (en) Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator
WO2026026912A1 (zh) 抗体药物偶联物和抗vegf抗体的联合应用
JP2024536201A5 (cg-RX-API-DMAC7.html)
CN120957726A (zh) 抗体-药物偶联物与癌症疗法的组合及其用途